Generic and biosimilar medicines: why copies are studied too

Thousands of identical pink tablets in a stainless-steel drum on a production line

Many medicines people take for years are copies of an original that came first. Before a copy can be sold, research has to show it does the same job. This guide explains generic and biosimilar medicines in plain words, what studies of a copy compare and what happens in studies where people move from an original medicine to its copy.

Generic medicines in plain words

A generic medicine contains the same active ingredient as the original, in the same strength and form, taken the same way. Its tablets may look different, because color, shape and the inactive fillers can change, but the part that treats the condition is the same. Many tablets for high blood pressure are taken as generics.

For a generic, research mainly checks that the same amount of the active ingredient reaches the blood at about the same speed as with the original. When it does, the generic is expected to work the same way.

Biosimilar medicines, and why they differ

Some medicines are made by living cells rather than mixed from chemicals. Many injected biologic medicines for psoriasis and ankylosing spondylitis are made this way. Because living cells never produce exactly the same thing twice, a copy of one cannot be identical. It is called a biosimilar.

A biosimilar has to be shown to be highly similar to the original, with no meaningful difference in how well it works or how safe it is. That takes more research than a generic, including studies in people with the condition.

What a study of a copy compares

A study of a copy usually puts it beside the original and measures the same things for both. The aim is not to find a better medicine but to show that the two behave alike in the body. Common points of comparison include:

  • How much of the medicine reaches the blood, and how fast
  • How well it controls the condition over the same weeks
  • Unwanted effects and how often they happen
  • Whether the body makes antibodies against it
  • How the pen, syringe or tablet feels to use

Studies where people move from an original to its copy

Some studies follow people who have taken an original medicine for a while and then move to its copy, sometimes going back and forth more than once. They check that control of the condition holds steady and that no new problems appear with the change.

In the United States, a biosimilar shown to work this way can be labelled interchangeable, which can allow a pharmacist to hand it over in place of the original, depending on state rules. Outside a study, a switch like this is something to talk through with your own doctor and pharmacist, never a change to make alone.

What this research means for you

Copies of a medicine often give more people a choice of treatment and more makers producing it. Studies of copies tend to use medicines whose effects are already well understood, which some people find reassuring when they first read about research.

Study Lookout writes about studies of copies the same way as any other medicine research: in general terms, naming no medicine and no maker. It sells and recommends nothing. If a study of a copy interests you, contact its team yourself and ask your doctor how it would fit with what you take now.

Points to keep

  • A generic medicine has the same active ingredient, strength and form as the original.
  • A biosimilar is a close copy of a medicine made by living cells, which cannot be identical.
  • Studies of a copy set it beside the original and look for the two to behave alike.
  • Some studies follow people as they move from an original medicine to its copy.
  • Study Lookout explains how copies are studied, while choosing a study and talking it over with your doctor remain yours.